AGYTF (Allergy Therapeutics) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGYTF Allergy Therapeutics PLC AGYTF
24 GF Score
Price $0.15
GF Value $0.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Allergy Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AGYTF
24GF Score
Allergy Therapeutics PLC AGYTF
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Allergy Therapeutics (AGYTF) Overvalued in 2026?

Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued. The current stock price of $0.15 is trading 400% above its estimated GF Value™ of $0.03. GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.

Key valuation signals for AGYTF:

  • Short Ratio:
  • GF Value™: $0.03 vs. price of $0.15 (400% above fair value)
  • GF Score™: 24/100 with 7 warning signs

No single metric tells the full story. See the AGYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allergy Therapeutics Business Description

Other Exchanges AGY:UKHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
24GF Score

Get the complete analysis for AGYTF

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.03
GF Value